Follicular lymphoma

Cover Page
  • Authors: Babicheva L.G.1, Tumyan G.S.1,2, Osmanov E.A.3,4, Falaleeva N.A.5, Kravchenko S.K.6, Stefanov D.N.7, Poddubnaya I.V.8, Myakova N.V.7, Rumyantsev A.G.7, Maschan A.A.7, Ptushkin V.V.9, Baikov V.V.10, Kovrigina A.M.11,12, Krivolapov I.A.13, Konovalov D.M.14, Nevolsky A.A.15, Ivanov S.A.15, Khaylova Z.V.5, Gevorkian T.G.16
  • Affiliations:
    1. FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia
    2. FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia
    3. FSBI “National Medical Research Center of Oncology named after N.N. Blokhin »Ministry of Health of Russia
    4. Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after I.M. Sechenov» Ministry of Health of Russia
    5. Medical Radiological Scientific Center. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia
    6. National Research Center for Hematology of the Ministry of Health of the Russian Federation
    7. FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia
    8. FSBEI DPO "Russian Medical Academy of Continuing Professional Education" of the Ministry of Health of Russia
    9. City Clinical Hospital named after S.P. Botkin
    10. FSBEI of HE “First St. Petersburg State Medical University named after Acad. I.P. Pavlov» Ministry of Health of Russia
    11. National Medical Research Center of Hematology, Ministry of Health of Russia
    12. Institute for Advanced Studies
    13. Mechnikov North-West State Medical University
    14. FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev »Ministry of Health of Russia
    15. Medical Radiological Scientific Center. them. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia
    16. Blokhin National Medical Research Center of Oncology
  • Issue: Vol 22, No 2 (2020)
  • Pages: 34-51
  • Section: Guidelines
  • URL: https://modernonco.orscience.ru/1815-1434/article/view/34877
  • DOI: https://doi.org/10.26442/18151434.2020.2.200131
  • Cite item

Abstract


Clinical recommendations.


Full Text

Restricted Access

About the authors

Lali G. Babicheva

FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Cand. med. Sciences, Assoc. dep. oncology and palliative medicine, vice-rector for medical work and international cooperation, member of the Russian Society of Oncohematologists

G. S. Tumyan

FSBEI DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia; FSBI “National Medical Research Center of Oncology named after N.N. Blokhina» Ministry of Health of Russia

Author for correspondence.
Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof., prof. cafe oncology and palliative medicine, Vedas. scientific al. Hemoblastosis chemotherapy department, member of the board of the Russian Society of Oncohematologists

E. A. Osmanov

FSBI “National Medical Research Center of Oncology named after N.N. Blokhin »Ministry of Health of Russia; Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after I.M. Sechenov» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof., head. Dep. hematology and bone marrow transplantation, prof. cafe oncology, member of the board of the Russian Society of Oncohematologists

N. A. Falaleeva

Medical Radiological Scientific Center. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Obninsk

Dr. med. sciences, head. Department of Anticancer Drug Treatment, Member of the Association of Oncologists of Russia and the Russian Association of Therapeutic Radiation Oncologists

S. K. Kravchenko

National Research Center for Hematology of the Ministry of Health of the Russian Federation

Email: or@hpmp.ru

Russian Federation, Moscow

Candidate of Medical Sciences, Head intensive intensive high-dose chemotherapy for hemoblastoses with a 24-hour and a day hospital FSBI NICT Hematology

D. N. Stefanov

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Москва

Researcher, Scientific and Organizational Department, Member of the Russian Society of Oncohematologists

I. V. Poddubnaya

FSBEI DPO "Russian Medical Academy of Continuing Professional Education" of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Acad. Russian Academy of Sciences, honored. Education Worker of the Russian Federation, Dr. med. sciences, prof., head. cafe oncology and palliative medicine, vice-rector for medical work and international cooperation, chairman of the Russian Society of Oncohematologists

N. V. Myakova

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof., deputy chapters. medical doctor, head Department of Oncohematology, member of the National Society of Pediatric Hematologists and Oncologists

A. G. Rumyantsev

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Acad. RAS, Dr. med. sciences, prof., gen. Dir., President of the National Society of Pediatric Hematologists and Oncologists

A. A. Maschan

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology n.a. Dmitry Rogachev» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Corr. RAS, Dr. med. sciences, prof., deputy gene. Dir., Member of the Board of the National Society of Pediatric Hematologists and Oncologists

V. V. Ptushkin

City Clinical Hospital named after S.P. Botkin

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof., deputy chapters. hematology doctor, chapters. Freelance specialist-hematologist of the Moscow Department of Health, member of the National Hematology Society and the Russian Society of Oncohematologists

V. V. Baikov

FSBEI of HE “First St. Petersburg State Medical University named after Acad. I.P. Pavlov» Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, prof. cafe pathological anatomy, head. lab. Pathomorphology Research Institute of Pediatric Oncology, Hematology and Transplantology. R.M. Gorbachev, Member of the Presidium of the Russian Society of Pathologists, Member of the Board of the Russian Society of Oncohematologists

Alla M. Kovrigina

National Medical Research Center of Hematology, Ministry of Health of Russia; Institute for Advanced Studies

Email: or@hpmp.ru

Russian Federation, Moscow

Dr. med. sciences, pathologist, prof. cafe pathological anatomy, cytology and molecular pathology; Head pathoanatomical department; Member of the Presidium of the Russian Society of Pathologists, Member of the Board of the Russian Professional Society of Oncohematologists, Member of the National Hematology Society

Iurii A. Krivolapov

Mechnikov North-West State Medical University

Email: or@hpmp.ru

Russian Federation, Saint Petersburg

д-р мед. наук, проф., врач-патологоанатом, зав. отд-нием клинической молекулярной морфологии; член президиума Российского общества патологоанатомов

D. M. Konovalov

FSBI National Medical Research Center for Pediatric Hematology, Oncology and Immunology Dmitry Rogachev »Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Moscow

Cand. med. sciences, head. pathological department

A. A. Nevolsky

Medical Radiological Scientific Center. them. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Obninsk

Dr. med. sciences, deputy Dir. on medical work

S. A. Ivanov

Medical Radiological Scientific Center. them. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Obninsk

prof. RAS, Dr. med. sciences, dir.

Zh. V. Khaylova

Medical Radiological Scientific Center. A.F. Tsyba - branch of the Federal State Budgetary Institution "National Medical Research Center of Radiology" of the Ministry of Health of Russia

Email: or@hpmp.ru

Russian Federation, Obninsk

Cand. med. sciences, deputy dir. on organizational and methodological work

Tigran G. Gevorkian

Blokhin National Medical Research Center of Oncology

Email: or@hpmp.ru

Russian Federation, Moscow

зам. дир. НИИ КЭР 

References

  1. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Ed. S.H.Swerdlow, E.Campo, N.L.Harris et al. 2017.
  2. Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997; 89 (11): 3909–18.
  3. Бабичева Л.Г., Тумян Г.С., Кравченко С.К. Фолликулярная лимфома. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 43–52.[Babicheva L.G., Tumian G.S., Kravchenko S.K. Follikuliarnaia limfoma. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 43–52 (in Russian).]
  4. Демина Е.А. и др. Общие принципы диагностики лимфом. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 9–27.[Demina E.A. et al. Obshchie printsipy diagnostiki limfom. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 9–27 (in Russian).]
  5. Мухортова О.В. Использование ПЭТ/КТ при лимфопролиферативных заболеваниях. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 168–79.[Mukhortova O.V. Ispol’zovanie PET/KT pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 168–79 (in Russian).]
  6. Криволапов Ю.А., Леенман Е.Е. Морфологическая диагностика лимфом. СПб.: Коста, 2006.[Krivolapov Iu.A., Leenman E.E. Morfologicheskaia diagnostika limfom. Saint Petersburg: Kosta, 2006 (in Russian).]
  7. Бокерия Л.А., Затевахин И.И., Кириенко А.И. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология. 2015; 4 (2): 3–52.[Bokeriia L.A., Zatevakhin I.I., Kirienko A.I. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniiu i profilaktike venoznykh tromboembolicheskikh oslozhnenii (VTEO). Flebologiia. 2015; 4 (2): 3–52 (in Russian).]
  8. Кириенко А.И., Галстян Г.М., Савченко В.Г. Профилактика венозных тромбоэмболических осложнений при лимфопролиферативных заболеваниях. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 268–78.[Kirienko A.I., Galstian G.M., Savchenko V.G. Profilaktika venoznykh tromboembolicheskikh oslozhnenii pri limfoproliferativnykh zabolevaniiakh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 268–78 (in Russian).]
  9. Шмаков Р.Г., Демина Е.А. Лимфомы и беременность. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 143–50.[Shmakov R.G., Demina E.A. Limfomy i beremennost’. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 143–50 (in Russian).]
  10. Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
  11. Dreyling M et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (Suppl. 5): v83–v90.
  12. Campbell BA et al. Long-term outcomes for patients with limited stage follicular lymphoma involved regional radiotherapy versus involved node radiotherapy. Cancer 2010; 116 (16): 3797–806.
  13. Wilder RB et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51 (5) 1219–27.
  14. Brady JL et al. Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: A collaborative study by ILROG. Blood 2019; 133 (3): 237–45.
  15. Ardeshna KM et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial. Lancet Oncol 2014; 15 (4): 424–35.
  16. Hiddemann W et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol 2018; 36 (23): 2395–404.
  17. Cheson BD et al. Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol 2018; 36 (22): 2259–66.
  18. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
  19. Dührsen U et al. Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med 2018; 7 (7): 2903–12.
  20. Поддубная И.В. Рецидивы фолликулярной лимфомы: проблемы и пути решения. Современная онкология. 2011; 1: 10–5.[Poddubnaia I.V. Retsidivy follikuliarnoi limfomy: problemy i puti resheniia. Journal of Modern Oncology. 2011; 1: 10–5 (in Russian).]
  21. Leonard JP et al. AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019; 37 (14): 1188–99.
  22. Sehn LH et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17 (8): 1081–93.
  23. Godfrey J, Leukam MJ, Smith SM. An update in treating transformed lymphoma. Best Pract Res Clin Haematol 2018; 31 (3): 251–61.
  24. Grignano et al. Radiotherapy of relapse-refractory follicular lymphoma. Cancer Radiother 2018; 22 (2): 126–30.
  25. Attarbaschi A et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a «watch and wait» strategy after complete resection. Ann Hematol 2013; 92 (11): 1537–41.
  26. Liu Q et al. Follicular lymphomas in children and young adults: A comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol 2013; 37 (3): 333–43.
  27. Kumar R et al. Rituximab in combination with multiagent chemotherapy for Pediatric follicular lymphoma. Pediatr. Blood Cancer 2011; 57 (2): 317–20.
  28. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
  29. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 251–3.[Bariakh E.A., Miakova N.V., Poddubnaia I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 251–3 (in Russian).]
  30. Aapro M и др. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.[Aapro M et al. Clinical recommendations for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).]
  31. Орлова Р.В. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 494–501.[Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 494–501 (in Russian).]
  32. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11.[Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol’nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).]
  33. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 289–311.[Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 289–311 (in Russian).]
  34. Srivastava S, Wood P. Secondary antibody deficiency-causes and approach to diagnosis. Clin Med 2016.
  35. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И.Пирогова Минздрава России, 2016. [Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).]
  36. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 278–88. [Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol’nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 278–88 (in Russian).]
  37. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
  38. Cheson BD et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol 2014; 32 (27): 3059–67.
  39. Solal-Céligny P et al. Follicular lymphoma international prognostic index. Blood 2004; 104 (5): 1258–65.
  40. Buske C et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006; 108 (5): 1504–8.
  41. Federico M et al. Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009; 27 (27): 4555–62.
  42. Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
  43. Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
  44. García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
  45. Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
  46. Huang YH et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31 (22): 2765–72.
  47. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
  48. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on interim-PET scan in lymphoma. Leukemia Lymphoma 2009; 50 (8): 1257–60.
  49. Khorana A et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10): 4902–7.

Supplementary files

Supplementary Files Action
1.
Appendix B. Patient Management Algorithms

Download (142KB) Indexing metadata

Statistics

Views

Abstract - 112

PDF (Russian) - 3

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies